Literature DB >> 12890206

Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol.

C J G Sanders1, H Van Weelden, G A A Kazzaz, V Sigurdsson, J Toonstra, C A F M Bruijnzeel-Koomen.   

Abstract

BACKGROUND: There is a clear relationship between ultraviolet (UV) radiation (UVR) and the clinical manifestations of patients with lupus erythematosus (LE). Cutaneous lesions are induced or exacerbated by exposure to UVR. Of patients with LE, 24-83% are reported to be photosensitive to UVR. LE tumidus appears to be the most photosensitive subtype of LE, followed by subacute cutaneous LE (SCLE). In general, the history of patients with LE correlates poorly with the presence or absence of photosensitivity, due to a delayed time interval between UV exposure and exacerbation of skin lesions. Phototesting using artificial UVR and visible light is a reliable way of diagnosing photosensitivity.
OBJECTIVES: To investigate the photoreactivity of patients with various subtypes of LE using an individualized phototest protocol. The results of phototests were correlated with the history of photosensitivity, the subtype of LE, the presence of autoantibodies and the use of anti-inflammatory medication by these patients.
METHODS: Phototesting with UVA, UVB and visible light was performed in 100 patients with LE. The diagnosis of LE was established both on clinical examination and skin histology. Serological studies were also performed in all patients. The phototests were performed on large skin areas of the forearm or trunk; the first dose was twice the minimal erythema dose and the dosage was increased according to the individual reactions of the patients at the test sites. Follow-up of skin reactions at the test sites was performed for up to 2 months. Histological examination of the photoprovoked skin lesions was carried out in 57 patients.
RESULTS: Of the 100 patients included (81 women and 19 men; mean age 41 years, range 17-79), 46 had chronic discoid LE, 30 SCLE and 24 systemic LE. An abnormal reaction to UVR and visible light was found in 93% of our patients with LE. No clinical or histological evidence at the phototest sites of polymorphic light eruption was found. There was no correlation between photosensitivity and LE subtype, presence of autoantibodies or medical history. Concomitant use of anti-inflammatory medication seemed to exert only minimal influence on the results of phototesting.
CONCLUSIONS: When using an extended phototesting protocol, almost all patients with LE in this study showed clinical and histological evidence of aberrant photosensitivity. Therefore, patients with LE should receive thorough advice and instruction on photoprotective measures, regardless of their history, LE subtype or presence of autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890206     DOI: 10.1046/j.1365-2133.2003.05379.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

1.  ELECTROPHYSICAL AGENTS - Contraindications And Precautions: An Evidence-Based Approach To Clinical Decision Making In Physical Therapy.

Authors: 
Journal:  Physiother Can       Date:  2011-01-05       Impact factor: 1.037

Review 2.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

3.  Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Renato Goreshi; Rachel Klein; Joyce Okawa; Mathew Rose; Andrew Cucchiara; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

4.  Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.

Authors:  Johann E Gudjonsson; J Michelle Kahlenberg; Mrinal K Sarkar; Grace A Hile; Lam C Tsoi; Xianying Xing; Jianhua Liu; Yun Liang; Celine C Berthier; William R Swindell; Matthew T Patrick; Shuai Shao; Pei-Suen Tsou; Ranjitha Uppala; Maria A Beamer; Anshika Srivastava; Stephanie L Bielas; Paul W Harms; Spiro Getsios; James T Elder; John J Voorhees
Journal:  Ann Rheum Dis       Date:  2018-07-18       Impact factor: 19.103

5.  Sunscreen use in patients with cutaneous lupus erythematosus.

Authors:  E L Gutmark; D Q Lin; I Bernstein; S Q Wang; B F Chong
Journal:  Br J Dermatol       Date:  2015-07-22       Impact factor: 9.302

6.  Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity.

Authors:  Mariela L Paz; Daniel H González Maglio; María Pino; Alejandro Ferrari; Federico S Weill; Gustavo Nasswetter; Juliana Leoni
Journal:  Clin Rheumatol       Date:  2010-05-19       Impact factor: 2.980

7.  Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells.

Authors:  Sonya J Wolf; Shannon N Estadt; Jonathan Theros; Tyson Moore; Jason Ellis; Jianhua Liu; Tamra J Reed; Chaim O Jacob; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Autoimmun       Date:  2019-06-24       Impact factor: 7.094

Review 8.  Photosensitivity in cutaneous lupus erythematosus.

Authors:  Andrew Kim; Benjamin F Chong
Journal:  Photodermatol Photoimmunol Photomed       Date:  2013-02       Impact factor: 3.135

9.  Epidermal injury promotes nephritis flare in lupus-prone mice.

Authors:  Kaitlyn L Clark; Tamra J Reed; Sonya J Wolf; Lori Lowe; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Autoimmun       Date:  2015-08-21       Impact factor: 7.094

10.  Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus.

Authors:  Lam C Tsoi; Grace A Hile; Celine C Berthier; Mrinal K Sarkar; Tamra J Reed; Jianhua Liu; Ranjitha Uppala; Matthew Patrick; Kalpana Raja; Xianying Xing; Enze Xing; Kevin He; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2019-02-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.